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1.1. Alzheimer’s disease 
The first case of Alzheimer’s disease (AD) was reported in 1906 by the German 
neuropathologist Alois Alzheimer (1864-1915) during the Meeting of South-West 
German Psychiatrists in Tubingen. He described the case of his 50-year-old 
patient who presented a specific clinical picture: she was suffering from paranoia, 
progressive sleep, memory disturbance, aggression, and confusion. 
After the patient’s death, Alzheimer and Gaetano Perusini, an Italian 
neuropsychiatrist, observed that the psychiatric symptoms could be correlated 
with the presence of particular cerebral lesions: peculiar plaques and 
neurofibrillary tangles [1]. 
Today AD is considered as the most common cause of dementia and it is 
recognized by the Word Health Organization as a global public health priority. 
AD affects about 5% of the population aged over 65 and 40% of the population 
aged over 80 [2]. More than forty-five million people are affected by the disease 
worldwide and this number is expected to grow to 131.5 million by 2050. 
The costs of coping with AD are enormous and, in 2010 only, 604 billion dollars 
have been spent. Despite the great force to resist the disease, no therapies have so 
far been able to prevent AD onset or progression [3-5]. 
The age, a positive family history and, to a lesser extent, the female sex, are the 










1.1.1. What is Alzheimer’s disease? 
Alzheimer's disease is a progressive, unremitting neurodegenerative disease 
characterized by cognitive impairment and memory loss. AD is thought to begin 
20 years or more before symptoms arise and it has an average clinical duration of 
8–10 years. 
Generally, the course of the disease is divided into three phases: an initial stage in 
which there is a slight cognitive deficit, an intermediate stage, until reaching a 
pathological severity defined as serious in the more advanced stages. 
Probably, the essential symptom of the disease, especially in the early stages of 
illness, is the memory impairment; in fact, although with different gravity, all 
mnemonic compartments are affected. Initially, there is in fact the tendency to 
forget apparently trivial everyday life circumstances; this constitutes the basis for 
those that will be much more severe cognitive deficits, such as, for example, not 
remembering familiar names or places.  
When the disease progresses, the patient shows difficulty speaking (aphasia) and 
becomes apathetic, feeling no interest for his/her daily activities. Activities that 
were important to the individual’s identity, such as planning family events or 
participating in sports, may no longer be possible. 
In the intermediate phase of the disease there is a progressive aggravation of the 
disorder; the subject is unable to learn new information and loses orientation even 
in familiar environments, due to the space-time disorientation and the early 
deficits of episodic memory.  
In the final stages of AD, people are bed-bound and need round-the-clock care. 
Symptoms occur because neurons in regions of the brain involved in thinking, 





In the most serious cases the terminal phase may arrive only after three years from 
the beginning of disease [4, 6].  
 
 
1.1.2. Genetics  
From the clinical point of view, two different forms of AD pathology are 
distinguished: the sporadic form (SAD) and the familial form (FAD). SAD, in 
which symptoms appear at age 65 or older (late-onset), is the most common and 
includes more than 99% of all cases [7]. The etiology of this form is still unknown 
and the pathogenesis has yet to be defined. FAD is characterized by autosomal 
dominant transmission and early onset, in fact individuals tend to develop 
symptoms before age 65. They are a small percentage of Alzheimer’s cases (1% 
or less) [8] and progress AD as a result of mutations to any of three specific 
genes.  
The first genetic mutation linked to dementia was identified on chromosome 21, 
in the locus coding for the amyloid precursor protein (APP) [9]. Other mutations 
have been identified in the genes coding for presenilin 1 (PS1) and presenilin 2 
(PS2), two enzymes involved in the production of β-amyloid (Aβ) [4].  
Mutations of these three genes are considered the most common cause of early 
AD, supporting the long-lasting “amyloid cascade hypothesis”, which considers 









1.1.3. Morphological alterations  




Figure 1 – Macroscopic morphological alterations of a brain with Alzheimer's disease 
 
The most evident macroscopic characteristic of the brain of a subject suffering 
from AD is the marked cortical atrophy, which determines an increased amplitude 
of the cerebral sulci and the increase of the ventricular volume, as illustrated in 
Figure 1. 
This atrophy appears widespread and is mainly linked to neuronal degeneration, 
which involves the reduction of dendritic spines and synaptic junctions, leading to 
death of the nerve cell through apoptotic processes. 
Studies conducted by Takashi Ohnishi and collaborators on AD brains described 
an important reduction of grey matter volume in the bilateral hippocampal 





Also Schott and colleagues showed that the mainly affected structures of AD 
brains are the hippocampus and the para-hippocampal gyrus of the temporal lobe 
and the cortical associative areas. On the contrary, the posterior areas of the 
hemispheres, the cerebellum and the brainstem are relatively spared [13]. 
In 1906 Alois Alzheimer first described the histopathological changes that 




Figure 2 - Neuritic plaques and neurofibrillary tangles. Immunohistochemistry of a 
hippocampal section. The anti--amyloid antibody reveals neuritic plaques, while the 
anti-PHF-1 antibody recognizes neurofibrillary tangles. 
 
Neuritic plaques, also called senile plaques or amyloid plaques [6], are 
extracellular and roundish structures with a diameter of 50-200 µm, which 
develop more abundantly in some areas of the brain such as hippocampus,  
parahippocampus and amygdala. The plaques are mainly constituted of aggregates 
of a 40-42 amino acids peptide called β-amyloid (Aβ). Around the plaques, two 





The neurofibrillary tangles (NFT) are intraneuronal aggregates of 
hyperphosphorylated and misfolded tau, a microtubule-associated protein. NFT 
accumulate in the cellular body of neurons, mainly in the hippocampus, entorhinal 
cortex, amygdala and basal forebrain nuclei, but when tangle-bearing neurons die, 
they become extracellular [14, 15]. 
 
 
1.1.4. How -amyloid is produced 
Aβ peptide is the main constituent of neuritic plaques and derives from the 
proteolysis of its precursor protein APP. APP is a type I transmembrane 
glycoprotein that is highly expressed in the central nervous system, where it exerts 
numerous physiological functions [16]. APP is also widely expressed in normal 
human tissues, including heart, lung, liver and skin. The APP gene is located on 
chromosome 21, thus justifying the Aβ overproduction and early development of 
AD in individuals with Down’s syndrome.  
APP has a large extracellular domain and a short intracytoplasmatic carboxy-
terminus called APP intracellular domain (AICD). As shown in Figure 3, APP 
can undergo cleavage in three different locations: at the N-terminal of the Aβ 
domain via β-secretase; at the C-terminal of the Aβ domain via γ-secretase; and 








Figure 3 – The sequential proteolytic processing  of amyloid precursor protein 
 
Under physiological conditions, α-secretase cleaves APP within the Aβ domain at 
residue L688, generating the soluble extracellular domain of APP (sAPPα) and 
the membrane-bound carboxy-terminal fragment of 83 amino acids (C83).  
The remaining C83 is further processed by γ-secretase to release a soluble P3 
peptide and the AICD intracellular domain, both rapidly degraded. This 
proteolytic pathway precludes the formation of Aβ because α-secretase cuts APP 
within its amyloidogenic sequence [18]. 
Alternatively, APP is cleaved by β-secretase, a transmembrane aspartic protease 
also called β-site APP Cleaving Enzyme (BACE1). BACE1 cleaves APP at Asp1 
site to generate C99 (and less frequently at Glu11 site to generate C89) and to 





secretase to produce one of several Aβ species, most commonly Aβ1-40 and Aβ1-42 
[17, 19], which are secreted into the extracellular space by exocytosis. 
The non-amyloidogenic pathway is particularly active on the plasma membrane 
[20, 21], where α-secretase is anchored; on the contrary, the amyloidogenic 
pathway prevails in the endo/lysosomal compartment, where the acidic 
environment favors BACE1 activity [22, 23].  
For long time it was thought that the α-secretase cut had a neuroprotective role, as 
opposed to the amyloidogenic one operated by BACE1 [24]. However, now we 
know that the β- and γ-secretase cleavages, respectively at the N- and C- terminal 
of Aβ, occur in physiological conditions, suggesting that all APP fragments, 
including Aβ, have a physiological significance [25, 26]. 
Aβ exists as a monomer, dimer and oligomer, and has a high propensity to form 
aggregates, such as protofibrils and fibrils, the main constituents of senile plaques 
in AD brains [27, 28]. 
Although Aβ1-40 is the most abundant form in healthy subjects and AD patients, 
however, Aβ1-42 has aroused huge interest due to its greater tendency to aggregate, 
forming oligomers with potential neurotoxic activity. 
 
 
1.1.5. The physiological role of Aβ 
Since the discovery of Aβ in 1984 [29], this peptide has been considered the 
central culprit of AD and, for this reason, the research has mainly been focused on 
its pathogenic role. However, over the years, there has been a considerable 
increase in the body of evidence suggesting physiological functions for APP, Aβ 





The first indirect proof of the promnesic role of Aβ dates back to the late 1990s, 
when it was evident that the intracerebroventricular administration of an anti-APP 
antibody weakened memory consolidation and recovery [31]. Two years later, Wu 
and colleagues reported that Aβ increases hippocampal long term potentiation 
(LTP) [32], while Tamaoka’s group demonstrated that Aβ1-40 levels in the 
cerebrospinal fluid (CSF) of AD patients are comparable with those of healthy 
subjects. Moreover, they also proved that the amount of Aβ1-42 (the most 
neurotoxic species) is significantly lower in the CSF of AD patients, compared to 
control subjects [33]. 
Another important evidence supporting the physiological role of Aβ is that APP 
knockout mice develop age-related cognitive deficits and LTP impairment [34-
36], suggestive of a positive effect of Aβ in synaptic plasticity and memory. In 
line with these observations, Saura and colleagues reported that the loss of 
presenilin, the enzymatic subunit of -secretase, impairs LTP and memory [37]. 
Upon further investigations, Puzzo and collaborators found that picomolar 
amounts of Aβ42 (similar to those produced physiologically in the healthy brain) 
enhance hippocampal LTP, while high (nanomolar) concentrations produce 
opposing results [38]. The same Authors have also shown that either anti-Aβ 
antibodies or APP knockdown impair LTP and cause cognitive deficits. Even 
more interestingly, these effects are abolished by intracranial administrations of 
picomolar Aβ42 [39]. 
The physiological function of Aβ on LTP and memory seems to be mediated by 
α7 nicotinic receptors (α7-nAchRs) [38, 39]. Indeed, Aβ has picomolar affinity for 
α7-nAchR [40] and enhances transmitter release in several brain regions including 





effect by blocking the post-synaptic receptor channel [41]. Accordingly, Puzzo 
and colleagues showed that Aβ fails to increase LTP in a mouse model where the 
α7-nAchR is knocked out [38]. 
A number of studies have also identified other possible targets of Aβ, for example 
NMDA receptors, RAGE (receptor for advanced glycation end-products), insulin 
receptor, cellular prion protein, and amylin receptor [42-44]. 
Considering all the evidences, a novel hypothesis has been proposed, according to 
which Aβ follows the rule of hormesis, favoring memory at picomolar 
concentrations and impairing it at higher levels [39, 45, 46]. Under this view, it 
could be envisaged that if Aβ would somehow lose its functions, a compensatory 
hyper-production mechanism could occur, leading to the cerebral peptide 
accumulation. 
Certainly, the complete failure of clinical studies aimed at clearing Aβ from the 















1.2. Cyclic nucleotides and memory  
Memory is the faculty of the brain to acquire, store and consolidate information, 
and understanding the molecular mechanisms of these processes is one of the 
main objectives of modern neurosciences. 
The second messengers cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP) are critically involved in the molecular 
pathways underlying memory formation and have important roles in 
neuroplasticity, which is generally regarded as the neural correlate of memory, i.e. 
long-term potentiation (LTP) [48].  
Pharmacological and genetic manipulations of the cAMP/PKA/CREB pathway 
alter the long-lasting form of LTP (L-LTP), which requires protein synthesis, is 
related to the late memory consolidation process, and is believed to be involved in 
the long-term memory (LTM) [49, 50]. 
cGMP has been studied for long time only with respect to the transient first phase 
of LTP, early-LTP (E-LTP), which is independent from gene expression and is 
related to the formation of the short term memory [51]. More recently, it has also 
been implicated in L-LTP and LTM [52, 53]. 
The increase of cAMP and cGMP by specific phosphodiesterase (PDE) inhibitors 
(PDE-Is) favors LTP and reduces cognitive deficits in animal models of AD, 
suggesting PDEs as potential therapeutic targets for the treatment of cognitive 
dysfunctions [54]. However, the exact role played by cAMP and cGMP in 








1.2.1. cGMP and the mechanism of memory formation 
cGMP is produced by guanylate cyclase (GC), which is activated by nitric oxide 
(NO) [55]. cGMP is quickly degraded by a group of PDEs that catalyze the 
hydrolysis of cGMP into 5’GMP. There are 11 PDE families and, among them, 
PDE 5, 6 and 9 are selective for cGMP, whereas PDE 1, 2, 3 and 10 can 
hydrolyze both cAMP and cGMP. 
cGMP activates the cGMP-dependent protein kinase (PKG), which in turn 
phosphorylates proteins that modulate the synthesis and/or the release of 
neurotransmitters [56]. 
In 1998, Son and collaborators indicated cGMP as one of the key intracellular 
second messengers in the N-methyl-d-aspartate (NMDA) signal transduction 
pathway that regulates synaptic plasticity [57]. Further studies by Serulle and 
colleagues demonstrated that the increase of cGMP activates signaling mediators 
such as the GMP-dependent protein kinase II (cGKII), which phosphorylates 
GluR1, an important promotor of synaptic plasticity [58]. 
In line with these studies, increasing cGMP levels by using PDE9 inhibitors 
improved LTP in hippocampal cultured neurons [59] and slices [60, 61].  
The memory-improving efficacy of PDE9 inhibitors has been proved in vivo using 
behavioral paradigms such as T-maze [62], object location [61] and novel object 
recognition test [59], in animal models. 
In humans, also because AD patients show reduced CSF levels of cGMP [63], 
inhibiting PDEs has been suggested as a possible strategy to ameliorate cognitive 





Despite the fact that it is not exactly clear how PDE-Is influence the processes of 
learning and memory in vivo, very recent findings indicate that Aβ is one of the 
downstream effectors for cAMP and cGMP to trigger synaptic plasticity [65, 66].  
 
 
1.2.2. The cGMP-Aβ correlation in cognitive processes 
Since cAMP, cGMP and Aβ peptides have been involved in the sustaining of LTP 
and memory, it became crucial to understand whether these three components are 
connected or acting independently from each other. 
Following this line of research, the lab where I worked at this thesis demonstrated 
that cAMP exerts positive effects on LTP through the stimulation of APP 
synthesis and Aβ production [67, 68]. 
Subsequently, also cGMP was proven to increase Aβ, but through a different 
mechanism: stimulating the convergence of APP and BACE-1 in endo-lysosomal 
compartments where the amyloidogenic processing of APP is favored [50, 65]. 
As previously observed with cAMP, cGMP could not support hippocampal LTP 
when specific anti-Aβ antibodies or APP
KO
 mice were used, but as soon as 
picomolar concentrations of synthetic Aβ were supplied, the LTP could be 
restored [65]. 
In Figure 4 is represented the theoretical model explaining how cGMP and cAMP 






















Figure 4 – Theoretical model explaining how cGMP and cAMP modulate Aβ leading to 
the enhancement of LTP. At presynaptic region, cAMP (green) stimulates Aβ production 
by inducing APP synthesis, whereas cGMP (blue) increases Aβ levels by modulating the 
processing of APP. In particular, cGMP favors the approximation of APP and BACE-1 in 
endo-lysosomal compartments. Once secreted, Aβ (red) might influence LTP by 
activating  postsynaptic receptors and/or the astrocytic α7 nicotinic acetylcholine 













1.3. Endocytic mechanisms 
Endocytosis is an important cellular mechanism by which cells generate small 
(60-120 nm) membrane vesicles used to transport various cargo molecules, 
extracellular ligands, membrane proteins and lipids from the cell surface to the 
internal compartments [69, 70]. 
Multiple mechanisms of endocytosis occur in eukaryotic cells and they are 
divided into two broad categories: phagocytosis or cell eating (the uptake of large 
particles) and pinocytosis or cell drinking (the uptake of fluid and solutes). 
Phagocytosis is the function of specialized cells (macrophages, neutrophils and 
monocytes) of ingesting and clearing foreign materials, such as pathogens or large 
debris. Pinocytosis, as shown in the Figure 5, includes four mechanisms: 
macropinocytosis, clathrin-mediated endocytosis (CME) [71], caveolae-mediated 





Figure 5 – Different processes of entry into the cell. These mechanisms differ from each 
other according to the size of the endocytic vesicle, the nature of the cargo and the 






Despite different endocytic pathways have been described, CME is the major 
route for the internalization of many cargoes and it is crucial for intercellular 
communication. 
Clathrin was first described in the 1960s as a regular protein coating the 
membrane of endocytic pits and vesicles in mosquito oocytes [73]. Clathrin is 
composed of three heavy chains, each of them binding a light chain to form a 
three-legged structure named triskelion. When the triskelia interact they assemble 
into a polygonal lattice, which helps to deform the overlying plasma membrane 
into a coated pit [70, 74]. 
Whatever the entry mechanism is, the cargo molecules are captured in the 
endosomes that are pinched off from the plasma membrane and then fuse with 
early or sorting endosome moving to final destination [69] . 
There are different types of endosomes and they can be designed as incoming 
endosomes, early endosomes, late endosomes or recycling endosomes, depending 
on the kinetics by which they are loaded with cargo and also with respect to their 
morphology [75]. Once endocytic vesicles have uncoated, they fuse with early 
endosomes, and then they mature into late endosomes before fusing with 
lysosomes for the cargo degradation [76]. 
The formation of transport vesicles and their specific delivery to target 










1.3.1. The role of Rab GTPases in regulating endocytosis 
Rab proteins are small GTPases that belong to the Ras superfamily and regulate 
the vesicular transport in endocytosis and exocytosis. There are over 70 human 
Rab GTPases and more than half of them are involved in regulating ensosomal 
membrane traffic [77, 78]. 
Rab GTPases define compartment identity and are principally implicated in 
vesicle formation, transport, docking and fusion to the target compartment. These 
different roles are supported by many Rab effector proteins [69]. 
The ubiquitous Rab GTPases Rab5, Rab4 and Rab11 function on the early 
endocytic pathway, whereas Rab7 and Rab9 function on the late endocytic 
pathway. Rab5 can also be detected at the plasma membrane [79]. 
Rab proteins are recruited to and activated on the donor membrane, where they 
are important in vesicle budding. In particular, activated Rab5 is involved in 
sequestering ligands into clathrin coated vesicles and in the subsequent vesicle 
fusion with early endosomes [80]. Rab7 acts downstream from Rab5 and regulates 
the transport from early to late endosomes and lysosomes, whereas Rab4 and 
Rab11 regulate the transport along the recycling pathway, from early and 
recycling endosomes to the cell surface [78]. 
Live-cell imaging studies conducted by Rink and colleagues have demonstrated 
that Rab5 levels at the endosomal membrane are not stable, but they fluctuate 
dynamically. Through repetitive fusion and fission events, the cargo into early 
endosomes becomes concentrated, while endosomes enlarge. On these large 
endosomes there is a complete loss of Rab5, which is replaced by Rab7. This 
conversion mechanism from Rab5 to Rab7 marks the transition of cargo from 





Rab proteins function in sequence and are activated and inactivated in a “cascade-
like” manner [81].  
 
 
1.3.2. The Rab activation cycle 
Rab proteins cycle between the cytosol and the membrane of their respective 
transport compartment [82].  
After translation, Rab is first associated with a Rab escort protein, which allows 
the C-terminal modification of Rab by the addition of one or two geranylgeranyl 
lipid groups. This change favors the Rab-membrane association when Rab is in 
the GTP-bound state (active state). A protein named GDP displacement factor 
(GDF) inserts Rab in the appropriate membrane, whereas a GDP dissociation 
inhibitor (GDI) mediates the membrane extraction of inactive Rab and leads to the 
formation of a cytosolic complex [83]. Figure 6 schematically illustrates this 
cycle: after membrane binding of Rab, a guanine nucleotide exchange factor 
(GEF) promotes the release of GDP and the subsequent loading of GTP. In its 
GTP-bound conformation, Rab is active and able to interact with specific effectors 
that, in turn, may trigger events such as vesicle fusion with a target membrane. To 
complete the cycle, a GTPase activating protein (GAP) binds to Rab and catalyzes 
the nucleotide hydrolysis, switching off the GTPase. The remaining GDP-bound 








Figure 6 – The Rab GTPase cycle. Rab proteins switch between two conformations: an 
inactive GDP-bound form and an active GTP-bound form. GEF allows the activation of 
Rabs by catalyzing the conversion from the GDP-bound to the GTP-bound form. After 
binding to specific effectors, active Rab promotes vesicle trafficking. GAP leads to Rab 
inactivation by  hydrolyzing the bound GTP to GDP. 
 
 
1.3.3. The role of Rabs in Alzheimer’s disease 
Rab proteins have been implicated in the trafficking of AD-related proteins; 
moreover, expression of certain Rab members was found to be affected in AD 
brains. These alterations have been related to endo-lysosomal dysregulation that 
may contribute to AD pathogenesis.  
In fact, enlargement of Rab5-positive early endosomes has been observed in the 
brain of AD patients together with the upregulation of Rab4, Rab5, Rab7, Rab10 






Another piece of evidence indicates that RIN3, a Rab5-GEF, is a risk factor for 
AD [86], whereas studies conducted by Ridge and collaborators suggest that the 
downregulation of Rab10 modulates Aβ42 levels and Aβ42/Aβ40 ratio in 
neuroblastoma cells [87]. 
Grbovic’s results have shown that Rab5 overexpression mimics the morphological 
changes in early endosomes seen in neurons from AD brains and demonstrated 
that the overactivation of this GTPase increases both Aβ40 and Aβ42 secretion in 
conditioned medium from murine fibroblast-like L cells stably transfected with 
human APP695 (L/APP) [88]. Accordingly, Xu reported an abnormal activation of 
Rab5 in post-mortem brain samples of AD patients and AD mouse models [89, 
90]. Moreover, Kim and colleagues demonstrated that elevated levels of the β-
cleaved carboxy-terminal fragment of APP (β-CTF) induce Rab5 overactivation 
by recruiting APPL1, a protein that stabilizes active GTP-Rab5 leading to 
pathologically accelerated endocytosis [91].  
In the light of current knowledge, it is likely to assume that alterations of Rab 
family members are somehow related to aberrant trafficking, signaling, and 
ultimately neurodegeneration, throughout the progression of AD. 
 
 
1.3.4. ADP-ribosylation factor proteins (Arfs) 
Arf proteins belong to a group of six small (20 kDa) GTPases. Like Rabs, they are 
related to the Ras family and their main function is that of maintaining the 
integrity of intracellular transport [92]. 






Three classes of Arf proteins are expressed in mammals: class I (including Arf 1, 
2 and 3), class II (including Arf 4 and 5), and class III (including only Arf 6) [93]. 
Arfs localize to the plasma membrane and to membranes of secretory, endosomal, 
and lysosomal pathways. Differently from the other Arf proteins, Arf 6 has no 
effect on Golgi membrane dynamics. It regulates the cortical actin cytoskeleton, 
the endosomal trafficking [69, 93], and the CME, [94, 95], although an alternative 
role of Arf 6 in clathrin- and caveolae- independent internalization mechanisms 
has been suggested [96]. 
 
 
1.3.5. APP and BACE1 trafficking 
After protein synthesis in the endoplasmic reticulum, both APP and BACE1 
mature through the constitutive secretory pathway.  
Most of APP is found in the Golgi complex and trans-Golgi network and only a 
small portion is detected at the cell surface. In fact, over 50% of mature APP is 
internalized within 10 minutes and sorted into early endosomes. Here, one 
fraction is recycled back to the plasma membrane and another fraction is targeted 
to lysosomes for degradation. 
BACE1 is also localized in the trans-Golgi network and endosomes and is rapidly 
internalized from the cell surface [97, 98]. However, APP and BACE1 do not co-
localize at the plasma membrane, where APP is generally cleaved by α-secretase. 
Rab5-positive early endosomes are the main compartments where BACE1 
encounters APP. In fact, the endosomal acidic environment is optimal for BACE1 





Recently, Sannerud and collaborators demonstrated that the internalization of 
BACE1 is independent of clathrin and requires Arf6 activity [99]. Differently, the 
trafficking of APP from the cell surface to Rab5-positive early endosome occurs 




Figure 7 – Schematic view of APP and BACE1 internalization. Under normal conditions, 
early endosomes marked by Rab5  are the main sites of APP processing by BACE1. APP 
undergoes internalization from the plasma membrane to early endosomes within clathrin-
coated vesicles, whereas BACE1 is sorted to early endosomes through a clathrin-
































































Previous data from the laboratory where I carried out this study demonstrated that 
the enhancement of cyclic guanosine monophosphate (cGMP) in neuronal 
microdomains triggers the interaction of APP and BACE1 in early endosomes. As 
a consequence, this induced the production of Aβ peptides, which was 
instrumental to sustain hippocampal long-term potentiation and memory 
formation [65].  
In light of these findings, the present study aimed to better characterize the 
trafficking of APP and BACE1 under cGMP stimulation in order to provide new 
molecular details that may improve our understanding of AD pathogenesis.  
As already mentioned in the Introduction, overactivation of Rab5 has been shown 
to cause endosome enlargement, one of the earliest pathological alterations 
observed in the brain of AD and Down syndrome patients [89]; furthermore, 
expression of a dominant-negative Rab5 mutant was found to reverse neuronal 
atrophy in Droshophila [90].  
Although early endosomes marked by this small GTPase represent the major site 
of APP processing by BACE1 [101, 102], the mechanism by which APP meets 
BACE1 in Rab5-positive endosomes is still unknown.  
The first objective of my research was to investigate whether cGMP plays a role 
in the internalization of APP from the cell surface to the endosomal compartment, 
thus explaining, at least in part, how the cyclic nucleotide stimulates APP to 
interact with BACE1 in early endosomes.   
Thereafter, we investigated whether Rab5 and/or Arf6 may mediate the effects 
induced by the cyclic nucleotide on the trafficking and the amyloidogenic 





































3.1. cGMP stimulates the internalization of APP 
Previous results from our laboratory demonstrated an increased co-localization of 
APP and BACE1 in primary neurons treated with vardenafil, an inhibitor of PDE5 
that enhances intracellular cGMP [65]. In particular, this co-localization was 
found to take place in endolysosomal vesicles, compartments where the activation 
of BACE1 is favored by the acidic pH [50]. 
Here, we first tested whether cGMP could somehow trigger the endocytosis of 
APP.  
To this aim, we used N2a cells overexpressing APP, as only a small fraction of 
the protein is normally present at the plasma membrane. Cells were exposed to 
vardenafil for different times (0-60 min) and then processed for cell surface 
protein biotinylation. Immunoblot analysis of the biotin-labeled proteins revealed 
that the amount of plasma membrane-bound APP decreases in a time-dependent 
manner after vardenafil treatment (-34% at 10 min-exposure, P < 0.01; -39% at 30 











Figure 8 – cGMP induces a faster APP internalization. N2aAPP cells were treated with 
100 M vardenafil (VDF) for the indicated time periods. Control samples (0 min) 
received the same volume of vehicle (DMSO) for 60 min. After cell surface biotinylation, 
followed by cell lysis and precipitation with NeutrAvidin
TM 
-beads, levels of APP in the 
plasma membrane were determined by immunoblot analysis with 22C11 antibody. The 
transferrin receptor (TfR) was used as a loading control. Results are expressed as mean  
SEM for at least four independent experiments. **P < 0.005 and ***P < 0.0001 vs. 
vehicle-treated group (one-way ANOVA, Dunnet post-test). 
 
 
In order to verify whether the reduction of APP on the cell surface may reflect its 
increased internalization, we performed a surface APP immunostaining on ice, 
without permeabilization [103], before incubating the cells with vardenafil for 10 
sec or 10 min at 37 °C. Using confocal microscopy analysis, we found that 10 sec 





both vardenafil and control cells (Figure 9, upper panels). At 10 min exposure, 
control cells showed an APP-associated fluorescence still located at or just 
beneath the plasma membrane, whereas a pronounced translocation of APP to 
intracellular vesicle-like puncta was observed in vardenafil treated cells (Figure 9, 





Figure 9 – Confocal images of N2aAPP cells incubated at 4 °C with the anti-APP 
antibody 6E10, as described in Materials and Methods, and then treated with 100 M 
vardenafil (VDF)  or DMSO (vehicle) for 10 sec or 10 min at 37 °C. Cells were then 
fixed, permeabilized and labeled with a green fluorescent secondary antibody. Figure is 









3.2. Inhibition of endocytosis prevents the amyloidogenic effect of 
cGMP 
Next, we investigated the impact of endocytosis on the cGMP-induced 
amyloidogenesis. To this aim, N2a cells were pre-treated with PitStop2, an 
inhibitor of both clathrin-dependent and clathrin-independent endocytic pathways 
[104], and then exposed to the cGMP-enhancer vardenafil. As expected, the 
inhibition of endocytosis per se reduced the production of Aβ peptides [105] (67% 
of control, P < 0.05), whereas vardenafil robustly increased it [50] (286% of 
control, P < 0.0001). Notably, the effect of vardenafil was totally prevented by 
PitStop2, indicating that the endocytic process is required for cGMP to increase 

















Figure 10 – The production of Aβ induced by cGMP is prevented by the inhibition of 
endocytosis. Where indicated, N2a cells were pretreated with 25 M  PITSTOP2 for 10 
min and then incubated for 1 h with 100 M vardenafil (VDF) or an equal volume of 
vehicle (Control). At the end of the incubation period, conditioned media were subjected 
to specific Aβ42 -ELISA. Graphed data show mean  ±  SEM for at least three independent 












3.3. Rab5 activation state modulates Aβ production 
Given the involvement of Rab5 [89] and Arf6 [99] in APP and BACE1 
endosomal trafficking, respectively, we evaluated the amount of Aβ peptides in  














) mutants. Efficiency of 
transfections in multiple experiments was assessed by immunoblot analyses, and 
typical levels of expression are shown in Figure 11A. Overexpression of either 
WT or mutant forms of HA-Arf6 did not alter the amount of Aβ released by the 
cells in the culture media, and similar results were obtained in mRFP-Rab5
WT
 
expressing samples (Figure 11B). On the contrary, overexpression of mCherry-
Rab5
DN
 increased the Aβ release (130% of control, P < 0.05), while a slight, but 
statistically significant decrease was observed in culture media of cells transfected 
with mCherry-Rab5
CA








Figure 11 – Rab5 but not Arf6 mutations influence Aβ production. Where indicated, N2a 













. After 24 h, cells were processed for total protein 
extraction, and immunoblot analyses were performed with anti-Rab5 and anti-HA 
antibodies to verify the efficiency of transfections (A), while conditioned media were 
subjected to specific Aβ42 -ELISA (B). The β-actin signal represents the internal loading 
control. Graphed data show mean  ±  SEM for at least three independent experiments. *P 








3.4 Rab5 siRNA increases Aβ peptides  
In order to confirm the correlation between Rab5 and Aβ, we induced Rab5 
transient knockdown in N2a cells using specific siRNAs. Forty-eight hours after 
siRNA transfections, conditioned media were subjected to Aβ ELISA, whereas 
cell extracts were analyzed for Rab5 expression by immunoblot. In line with the 
effect exerted by Rab5
DN
, silencing of Rab5 significantly increased the amount of 
Aβ released by the cells in the culture medium (131% of non-targeting control 
siRNA, P < 0.05).  
 
 
Figure 12 – Rab5 siRNA increases Aβ production. N2a cells were transfected with Rab5 
siRNA or non- targeting siRNA (CNT siRNA).  After 48 h, media were changed and 
collected 1 h later for Aβ42-ELISA. At the same time, cells were processed for Rab5 
immunoblotting. The β-actin signal represents the internal loading control. Graphed data 








3.5. cGMP reduces GTP-Rab5 levels 
We next sought to examine whether an increase of intracellular cGMP could 
influence the activation of Rab5. As a small GTPase, Rab5 cycles between a 
GDP- (inactive) and GTP-bound form (active) [106]. Therefore, we measured 
GTP-Rab5 levels in cells exposed to vardenafil for different times (5, 10, 30 and 
60 min). As shown in Figure 13, an approximately 50% reduction of active GTP-
bound Rab5 was already evident, although not statistically significant, after 5 min 
of vardenafil treatment (P = 0.088 vs control). The amount of GTP-Rab5 dropped 
to 40% of control after 10 min (P < 0.01) and remained depressed after 30 and 60 
min of treatment (45% of control, P < 0.05, at both time points). Because the total 
expression of Rab5 did not change at any time of vardenafil exposure (Figure 13, 
Total Rab5 panel), it is likely to assume that cGMP increased the inactive GDP-



















Figure 13 – cGMP inhibits Rab5 activity. N2a cells were treated with 100 M vardenafil 
(VDF) for different times (5, 10, 30, 60 min). Control samples (0 min) received the same 
volume of vehicle (DMSO) for 60 min. At the end of treatments, cells were processed for 
total protein extraction followed by Rab5 activity assay, as described in the Material and 
Methods section. Top, representative immunoblots; bottom, graphed data showing mean  













3.6. cGMP decreases Rab5 activity without modifying full-length 
APP or CTFs expression 
Recently, Kim and collaborators shown that β-CTF, the APP soluble fragment 
generated by BACE1, is able to affect Rab5 activity [91]. To investigate whether, 
in our conditions, the inhibition of Rab5 could be due to the increase of β-CTF 
levels, we analyzed the APP fragments produced by the cells after vardenafil 
treatments. β-CTFs are rapidly cleaved by -secretase to generate Aβ peptides, 
therefore, to allow their detection, we pre-treated the cells with 2 µM DAPT, a -
secretase inhibitor.   
As shown in Figure 14, vardenafil did not modify the levels of full length APP or 
those of C99 and C89, the main β-CTFs. Moreover, also the C83 fragments 
generated by α-secretase were not affected by the cell treatment. 
These data indicate that the effect exerted by cGMP on the activation state of 
Rab5 is not mediated by the products of APP cleavage. The possibility that Aβ 
peptides could indeed play a role in the observed phenomenon was already 












Figure 14 – cGMP does not affect APP and its fragments. Expression of APP and CTFs 
in N2aAPP cell treated with vardenafil (VDF). Left, representative immunoblot analysis 
performed with an  anti-APP-CTF  antibody; right, graphed data showing mean  ±  SEM 
for at least three independent experiments. The β-actin signal represents the internal 




















 mutant stimulates APP and BACE1 interaction 
Using the Optical Convergence of APP and BACE1 (OptiCAB) assay [107], 
previous studies from our laboratory demonstrated that cGMP stimulates the 
interaction between APP and BACE1 [65]. Here, given the effect of vardenafil on 
the activation state of Rab5, we took advantage of the OptiCAB assay to 
investigate whether the overexpression of Rab5
DN
, which has a much higher 
affinity for GDP compared to GTP, could modify the approximation between APP 
and BACE1. To this aim, 16 hours after mCherry-Rab5
DN
 transfection, N2a cells 
were further transfected with APP tagged with the N-terminal fragment of the 
Venus fluorescent protein (APP:VN) and with BACE1 tagged with the 
complementary C-terminus (BACE1:VC). In this manner, the physical 
approximation of APP:VN and BACE1:VC allows the reconstitution of Venus 












Figure 15– OptiCAB assay. APP and BACE1 are respectively tagged with the N-terminal 
(VN) and the C-terminal (VC) portion of Venus protein. When APP interacts with 
BACE1, Venus fluorescence is reconstituted. 
 
 
Confocal microscopy analysis showed that the expression of Rab5
DN
 is able to 
increase APP-BACE1 approximation (Figure 16), which is suggestive of an 
increased interaction between BACE1 and its substrate. As a matter of fact, this 
effect exactly resembled that induced by the cGMP-enhancer vardenafil. 
Accordingly, in cells overexpressing Rab5
CA
, APP and BACE1 showed a reduced 









Figure 16 – Rab5
DN
 mutant triggers the interaction between APP and BACE1. For 
confocal analyses, N2a cells were transfected with APP:VN and BACE1:VC expressing 









), or underwent vardenafil treatment (VDF). Nuclei are blue-
fluorescent, the green fluorescence is indicative of APP-BACE1 interaction, whereas the 
red fluorescence is due to the expression of mutant mCherry-Rab5. Note the increase in 
the APP-BACE1 interaction in cells treated with vardenafil, compared to control cells, 
and how this effect is mimicked by Rab5
DN
 but not Rab5
CA
 expression. The inset shows 
merged blue/green fluorescence, and mCherryRab5 expression, at a great magnification. 
White scale bar = 50 m; black scale bar = 20 m. Figure is representative of 3 
























































The laboratory where I worked at this thesis demonstrated that cGMP stimulates 
the approximation of APP and BACE1 in endolysosomal compartments, 
consequently increasing the production of Aβ peptides [65]. 
To further investigate this issue, the project of my PhD focused on the 
identification of the mechanism by which cGMP regulates the subcellular co-
localization of APP and BACE1.  
Firstly, we provided evidence that cGMP has a role in the endocytic pathway of 
APP. In fact, our results indicate that cGMP is able to speed up the internalization 
of APP from the plasma membrane to endosomal compartments where BACE1 is 
preferentially active. Moreover, we found that the amyloidogenic effect of cGMP 
is abolished by PitStop2, an inhibitor of both clathrin-dependent and clathrin-
independent endocytic pathways, indicating that endocytosis is necessary for 
cGMP to increase Aβ. 
Secondly, we investigated the involvement of two GTPases, Rab5 and Arf6, 
respectively implicated in APP and BACE1 endocytic sorting. Our findings 
demonstrated that Rab5, but not Arf6, has an impact on the production of Aβ 
peptides. Specifically, we found that expression of a dominant mutant that keeps 
Rab5 in its inactive (GDP-bound) form increases the amount of Aβ peptides 
released by the cells, thus mimicking the effect of cGMP [65]. Moreover, Aβ 
levels are increased when Rab5 expression is knocked down by siRNA.  
This result prompted us to investigate whether cGMP could influence the 
activation state of Rab5, consequently leading to the observation that the cyclic 





Finally, we found that expression of the inactive Rab5 mutant increases APP-
BACE1 interaction, an effect previously detected in primary neurons treated with 
vardenafil [65], and confirmed in the present study.  
Taken together, these results suggest that the well-established positive effects 
exerted by cGMP on synaptic plasticity and memory formation [66] may require 
low Rab5-GTP levels, thus explaining, at least in part, why the upregulation of the 
small GTPase is associated with neurodegenerative phenomena [89]. Consistent 
with this hypothesis, a new transgenic mouse model of neuronal Rab5 over-
activation was very recently shown to develop AD-related endosome dysfunction 
and AD-like deficits in axonal transport, synaptic plasticity, cognition, and 
neuronal survival [108].  
Another important evidence in the present study is that the inactivation of Rab5 
correlates with an increased production of Aβ peptides, an event that, based on the 
“amyloid hypotesis” of AD [11], would generate detrimental consequences. 
Indeed, our data fit well with the notion that Aβ boosts hippocampal activity by 
regulating synaptic vesicle release [109], and with the studies of Puzzo and 
collaborators, who clearly demonstrated that physiological (picomolar) 
concentrations of Aβ42 are required to sustain LTP and cognitive performance [38, 
39].  
On the other hand, our findings seem at variance with previous reports showing 
that overexpression of either wild-type Rab5 [88], or dominant negative Arf6-
T27N increases the production of Aβ peptides. It should be noted, however, that 
those studies have been performed in non-neuronal cells engineered to 
overproduce Aβ, thus under different conditions that might justify the different 





production in mice expressing over-activated neuronal Rab5, despite the 
occurrence of AD-like deficits [108].  
Collectively, our data support a model in which cGMP favors the endosomal 
interaction between APP and BACE1 by keeping Rab5 in its GDP-bound 
conformation, consequently leading to the production of Aβ peptides that, in turn, 




Figure 16 – Theoretical model illustrating the cGMP-LTP pathway. At presynaptic level, 
the enhancement of cGMP keeps Rab5 in its GDP-bound conformation, thus decreasing 
GTP-Rab5 levels and allowing APP to interact with BACE1 in early endosomal 











It remains to be clarified how cGMP preserves the GDP-bound conformation of 
Rab5. In this respect, it can be hypothesized an involvement of Rab5-GAP, the 
protein that hydrolyses GTP to GDP, or Rab5-GEF, which is known to activate 
Rab5 [83]. Furthermore, an effect of cGMP on the activity of other Rab proteins 
cannot be excluded at this stage of the study. Rab7 and Rab4, for example, have 
been involved in the maturation of early endosomes and implicated in the 
recycling of APP from early endosomes to the plasma membrane  [81, 110].  
Another possibility is that suggested by Bucci and collaborators, who 
demonstrated that cells overexpressing dominant inactive Rab5 are characterized 
by smaller endocytic structures [106]. Accordingly, hyperactivation of Rab5 has 
been associated with enlarged early endosomes, an abnormality visible in sporadic 
AD brains [84]. Since cGMP favors the inactive state of Rab5, it is therefore 
possible that smaller endosomes make the approximation of APP and BACE1 
easier. 
 
Although we are still far away from elucidating the complete picture, novel 
molecular players governing the dynamics of Aβ production are beginning to 
emerge. Certainly, the more we learn on the physiology of APP and its 
processing, the closer we get to understanding AD and finding effective 
pharmacological treatments.  
From this prospective, increasing cGMP levels with PDE5 inhibitors could 
represent a promising therapeutic strategy. As a matter of fact, a study 
investigating repeated administrations of udenafil in  patients suffering from 
erectile dysfunction has shown beneficial effects on memory performance as well 





For a more complete information, however, it must be said that, in healthy 
subjects, single vardenafil administration did not enhance cognition or 






























































5.1. Cell culture and treatments 
Mouse Neuro-2a (N2a) cells were grown in 50% Dulbecco modified Eagle’s 
medium (DMEM) (Euroclone S.p.A., Italy), 50% OptiMEM (Invitrogen, 
Carlsbad, CA) with 0.1 mM non-essential amino acids, 1% penicillin-
streptomycin mixture, and 5% fetal bovine serum (FBS).  
N2a cells stably expressing wild-type human APP695 (N2aAPP) were obtained 
from Peter Davies (Albert Einstein College of  Medicine, Bronx, NY) and grown 
in the same culture medium with 200 g/ml geneticin (G418). 
Vardenafil (VDF), Pitstop2 and DAPT (Sigma-Aldrich, Italy) were dissolved in 
dimethyl sulfoxide (DMSO) and stored at -20°C until use.  
 
 
5.2. Total protein extraction from N2a cells 
N2a cells were lysed with an ice-cold buffer containing 1 mM EGTA, 50 mM 
NaF, 2 mM EDTA, 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 
1 mM PMSF, 1% protease inhibitors (Complete Mini, Roche S.p.A., Germany) 
and 1% SDS. Cell lysates were spun at 15,000 x g for 10 min at 4°C and the 
supernatant (total protein extracts) stored at -80°C until use. 
 
 
5.3. Protein quantification  
The total protein concentration was determined with bicinchoninic acid assay 
(Pierce BCA Protein Assay Kit, Thermo Scientific, Rockford, USA). This is a 
colorimetric method which combines reduction of Cu2+ to Cu+ by proteins in an 





to purple in proportion to the protein concentration. The intense purple-colored 
reaction product results from the chelation of two molecules of BCA with one 
cuprous ion, making a water-soluble complex. The amount of proteins is then 




5.4. Immunoblot analysis 
Immunoblot analysis, also called Western blotting (WB), is a biochemical 
procedure that allows a semi-quantitative evaluation of specific protein 
expression.  
In this technique, proteins are separated by electrophoresis in polyacrylamide gel 
[71], in the presence of SDS (SDS-PAGE). We used Bio-Rad Mini-gels system 
with precast gel (10 x 7.5 x 0.1 cm, 4-20 % polyacrylamide) and the standard 
Laemmli method [113]. 
Electrophoresis was performed at 140 V with a short pre-run at 70 V. At the end 
of the run, proteins were transferred from the gel to a polyvinylidene difluoride 
membrane (PVDF) using the Towbin method [114], with a cold buffer containing 
25 mM Tris, 192 mM glycin and 20% methanol. Transfer of proteins from gels to 
PVDF membranes occurred applying a current of 100 V for 60 min. Membranes 
were then incubated with a solution of TBS tween (t/TBS: 200 mM Tris, 1,3 M 
NaCl, pH 7.5, 0,05% tween 20) and 5% milk powder, in order to saturate possible 
nonspecific antibody binding sites.  
We used the following primary antibodies: monoclonal mouse anti-human APP 





receptor (1:1000; Invitrogen, USA), monoclonal rabbit anti-Rab5 (1:1000; 
Abcam, UK), polyclonal rabbit anti-hemagglutinin (anti-HA) (1:1000; Sigma-
Aldrich, Italy), rabbit anti-APP-CTF (1:1000; Zymed, USA) and monoclonal 
mouse anti-β-actin (1:10000; Sigma-Aldrich, Italy). At the end of incubations 
with the primary antibody, membranes were washed with t/TBS and incubated 
with a secondary anti-rabbit or anti-mouse antibody coupled to horseradish 
peroxidase (GE Healthcare, Little Chalfont, UK). Proteins were revealed with an 
enzyme-linked chemiluminescence detection kit (ECL, GE-Healthcare, Little 
Chalfont, UK). Chemiluminescence was visualized by film exposure, and signals 
were analyzed under non- saturating conditions with an image densitometer (Bio-
Rad, Hercules, CA). 
 
 
5.5. Cell surface biotinylation 
N2aAPP cells were treated with 100 M VDF for 5, 10, 30 and 60 min. Control 
samples (0 min) received the same volume of vehicle (DMSO) for 60 min.  
At the end of treatments, N2aAPP cells were surface biotinylated by incubation 
with Sulfo-NHS-SS-Biotin (Pierce Biotechnology, USA) at 2 mg/ml in PBS for 
30 min at 4 °C. Cells were then quenched with 100 mM glycine and lysed in 2mM 
EGTA, 10 mM NaF, 1 mM Na3VO4, 5 mM EDTA, 150 mM NaCl, 50 mM Tris-
HCl (pH 7.4), 1mM PMSF, 1% protease inhibitor cocktail, and 1% SDS. After 
centrifugation at 15,000 x g for 10 min, supernatants were incubated for 2 h at 
4°C with NeutrAvidinTM Protein immobilized onto 6% crosslinked beaded agarose 
(Pierce Biotechnology, USA), spun and subjected to SDS-PAGE and immunoblot 





5.6. Cells surface APP labeling  
N2aAPP cells were grown overnight on culture slides and then incubated for 1 h 
at 4 °C with the anti-APP monoclonal antibody 6E10 (1:200; Covance, USA). 
Cells were then washed and treated with 100 M VDF (or an equal volume of 
DMSO) for 10 sec or 10 min at 37°C. After fixing and permeabilization with ice-
cold methanol cells were labeled with the Alexa Fluor 488 goat anti-mouse IgG 
(1:500; Invitrogen, USA) and analyzed with a Leica TCS SP2 confocal 
microscope. To confirm the specificity of the fluorescence-associated signal, we 
performed the labeling in permeabilized cells that were not pre- incubated with 
the anti-APP antibody. 
 
 
5.7. Test ELISA for Aβ1-42 
Aβx-42 ELISA kit (Wako Chemicals GmbH, Germany) was used to measure Aβ 
peptides released into culture media from N2a cells. At the end of cell treatments, 
conditioned media were collected, spun at 1,000 x g to remove cell debris, and 
stored at -80°C until use. This ELISA test takes advantage of 96 well-plates 
coated with the monoclonal antibody BNT77, which binds to the amino acid 
sequence 11-28 of Aβ. Captured Aβ1-42 is then recognized by another antibody 
(BC05 HRP-conjugated), that specifically detects the C-terminal portion of Aβ1-42. 
The peroxidase activity is revealed after addition of 3,3’,5,5’-
Tetramethylbenzidine, a specific substrate of HRP. Positive samples develop a 
blue color. The reaction is stopped by the addition of sulfuric acid, which 
produces a yellow color proportional to the concentration of the antigen-antibody 





spectrophotometer (Bio-Rad iMark™). Aβ1-42 concentrations were calculated 
according to the standard curves prepared on the same ELISA plates. 
 
 
5.8. Plasmids and transfections  
mRFP-Rab5 (Addgene plasmid # 14437) was a gift from Ari Helenius (Institute 
of Biochemistry, Swiss Federal Institute of Technology, Zurich) [115]; mCherry-
Rab5CA (Q79L) (Addgene plasmid # 35138) and mCherry-Rab5DN (S34N) were 
a gift from Sergio Grinstein (Division of Cell Biology, Hospital for Sick Children, 
Toronto) [116]. Plasmids encoding Arf6 proteins (HA-Arf6WT, HA-Arf6Q67L 
and HA-Arf6T27N) were provided by Anna Fassio (University of Genoa). 
APP:VN (APP tagged with Venus N-terminal fragment) and BACE1:VC 
(BACE1 tagged with complementary Venus C-terminal fragment) plasmids were 
obtained from Subhojit Roy (University of California, San Diego, La Jolla). N2a 
cells were transiently transfected using Lipofectamine 2000 (Invitrogen, USA) at 
2 l/g DNA. 
 
 
5.9. RNA interference  
Accell Mouse Rab5a siRNA – SMART pool, as well as the control Accell Non-
targeting siRNA, were purchased from Dharmacon (Lafayette, USA). 
Transfections were performed according to the manufacturer’s instructions and 







5.10. Rab5 activity  
N2a cells were grown overnight on 10 cm culture dishes and then treated with 100 
M VDF for different time periods (5, 10, 30, 60 min). Control samples (0 min) 
received the same volume of vehicle (DMSO) for 60 min. At the end of 
treatments, cells were lysed and Rab5 activity was analyzed with the Rab5 
Activation Assay Kit (NewEast Biosciences, USA). According to the 
manufacturer’s instructions, cell lysates were incubated with a mouse anti-active 
Rab5 monoclonal antibody and the immunocomplex was then pulled down by 
protein A/G agarose. Levels of active Rab5 were quantified by immunoblot 
analysis using a rabbit anti-Rab5 polyclonal antibody. 
 
 
5.11. APP-BACE1 interaction assay 
To evaluate the approximation between APP and BACE1 we used the Optical 
Convergence of APP and BACE1 (OptiCAB) assay [107], which is based on the 
bimolecular fluorescence complementation of Venus protein fragments [117]. 
In this assay APP is tagged to the N-terminal fragment of the Venus protein 
(APP:VN) and BACE1 is tagged to the complementary C-terminal fragment of 
Venus (BACE1:VC). When APP:VN and BACE1:VC interact, Venus protein is 
reconstituted and fluorescent. Transfections of APP:VN and BACE1:VC 









5.12. Confocal analysis  
N2a cells were grown overnight on culture slides and transiently transfected with 
mCherry-Rab5DN (S34N) where indicated. After 16 hours, cells were further 
transfected with APP:VN and BACE1:VC expressing vectors and, 6 hours later, 
incubated with DMSO or VDF (50 M) for 16 hours. At the end of treatments, 
cells were permeabilized and fixed with ice-cold methanol, incubated with TO-
PRO
TM
-3 Iodide (Thermo Fisher Scientific, USA) for nuclear staining, and 
observed with the appropriated filters on a Leica TCS SP2 confocal microscope 
(planapochromat x 60 oil-immersion objective, numerical aperture 1.4).  
 
 
5.12. Statistical analysis 
Data were analyzed using one-away ANOVA followed by Dunnet’s post-hoc. 
Result are expressed as mean  standard error of the mean (SEM). The level of 
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